Form 4: 2seventy bio Director Charles W. Newton Disposes of Shares in Bristol-Myers Squibb Merger

Director Charles W. Newton reports the disposal of shares and stock options in 2seventy bio, Inc. following the merger with Bristol-Myers Squibb Company.

Summary

• Charles W. Newton, a director of 2seventy bio, Inc., filed a Form 4 detailing changes in beneficial ownership of the company's securities.
• The filing reports transactions related to the merger between 2seventy bio and Bristol-Myers Squibb Company, which became effective on May 13, 2025.
• As part of the merger agreement, shares of common stock were acquired by Bristol-Myers Squibb at a price of $5.00 per share.
• Restricted stock units (RSUs) held by Newton vested and were converted into the right to receive cash equal to the merger consideration for each underlying share.
• Newton's stock options with an exercise price less than $5.00 were also converted into the right to receive cash equal to the difference between the merger consideration and the exercise price.
• Stock options with an exercise price equal to or greater than $5.00 were cancelled for no consideration.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document primarily reports factual information about the completion of a merger.

Future Outlook

The merger between 2seventy bio and Bristol-Myers Squibb is complete, with 2seventy bio now a wholly-owned subsidiary of Bristol-Myers Squibb.

Industry Context

This announcement reflects ongoing consolidation within the biotechnology industry, where larger pharmaceutical companies acquire smaller firms with promising technologies or drug candidates.

Stakeholder Impact

• Shareholders received $5.00 per share as part of the merger agreement.
• Employees may experience changes as 2seventy bio becomes a subsidiary of Bristol-Myers Squibb.

Key Dates

Keywords

Form 4, Merger, 2seventy bio, Bristol-Myers Squibb, Beneficial Ownership, Securities, Director, Newton, TSVT